What Корвитол treats: Main Uses and Benefits

The medication is commonly used to help with several chronic and episodic conditions. The overall goal is to provide support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.

Корвитол is applied in addressing Hypertension (high blood pressure) and is relevant for patients experiencing conditions marked by increased physiological stress. The medication plays a role in managing conditions such as Angina Pectoris (chest pain), certain heart rhythm disorders, and is commonly used in situations involving the supportive management of symptoms following a heart attack. This use provides supportive relief that helps patients cope more steadily with difficult episodes.

It is relevant for easing the symptomatic burden of stable, symptomatic Chronic Heart Failure (CHF). This treatment contributes to easing the overall symptom load and assists with maintaining functional stability. Furthermore, it is applied when appropriate for prophylaxis in situations involving recurrent or episodic manifestations, such as managing the symptomatic burden of migraine attacks.

---

Quick Fact: Relevant for Symptoms linked to Organ-Specific Functional Stress and Episodic Manifestations

---

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility for Корвитол (Metoprolol): Official Regulatory Information

The eligibility for using Корвитол is strictly defined by regulatory authorities and centers on avoiding use in populations with pre-existing conditions that the medicine could worsen. Use is established primarily for adult patients across all approved indications. Pediatric use is restricted to children aged 6 years and older for the treatment of hypertension only; use in children under 6 years is not established.

---

Population Status	Regulatory Classification (Examples)
Absolute Contraindication	Cardiogenic shock, decompensated heart failure, severe bradycardia, second- or third-degree Atrioventricular (AV) block (without a pacemaker), and known hypersensitivity.
Restricted or Conditional Use	Severe hepatic impairment, bronchial asthma/COPD, and diabetes mellitus (due to the potential for masking hypoglycemia symptoms).
Reproductive Status	Use in pregnancy and lactation is generally not recommended unless judged strictly necessary due to documented risks to the infant or fetus.

---

Regulatory documents mandate these constraints. Patients with mild to moderate renal impairment typically do not require dose adjustment, but those with severe hepatic impairment require specific caution and may need lower starting doses.

Interactions with other medicines and products

Корвитол (Metoprolol) has officially documented interactions with several drug classes and specific medicines, primarily affecting its concentration in the body or enhancing its effect on the heart and blood pressure. Co-administration with strong CYP2D6 Inhibitors (such as quinidine, fluoxetine, and paroxetine) is documented to increase the concentration of metoprolol, potentially requiring close monitoring of the patient.

Simultaneous use with other medicines that slow the heart rate, including Digitalis glycosides and certain Calcium Channel Blockers (e.g., diltiazem, verapamil), may result in an additive effect, significantly increasing the risk of bradycardia and/or impaired atrioventricular conduction. Similarly, Catecholamine-Depleting Drugs (e.g., reserpine, MAO inhibitors) may cause marked hypotension or bradycardia due to their additive effects with metoprolol.

A specific procedural requirement exists for the antihypertensive drug Clonidine. If Clonidine therapy is being withdrawn, metoprolol must be discontinued gradually several days before the gradual withdrawal of Clonidine to avoid the risk of severe rebound hypertension. Furthermore, patients with a history of severe allergic reactions taking metoprolol may be unresponsive to the usual doses of epinephrine used to treat anaphylaxis.

Selective beta1 Receptor Blockade in the Heart

The primary mechanism of Корвитол (Metoprolol) is the competitive antagonism of the beta1-Adrenergic Receptors (beta1 AR), found predominantly in the cardiac tissue. By blocking the binding site of stimulating hormones like adrenaline (catecholamines), this action suppresses the excitatory signaling mediated by the sympathetic nervous system.

---

Intracellular Signaling and Cardiac Modulation

Blocking the beta1 AR halts the associated intracellular signaling cascade, specifically reducing the production of the secondary messenger cAMP and subsequently limiting the activity of L-type Calcium Channels. This mechanistic sequence results in two primary physiological changes: a negative chronotropic effect (slowing the heart rate) and a negative inotropic effect (decreasing the force of myocardial contraction).

---

Systemic Neurohormonal Modulation

The mechanism extends beyond the heart to include beta1 AR in the kidney, where their blockade suppresses the release of Renin. This action modulates the Renin-Angiotensin-Aldosterone System (RAAS), influencing the drug's systemic physiological consequences. This selectivity is dose-dependent, with a loss of beta1 specificity occurring at higher concentrations.

How to Use Корвитол: Official Administration Instructions

This section outlines the regulatory-approved principles for administering Корвитол (Metoprolol), focusing solely on the official instructions for dosage and use as defined by government health authorities. It excludes all safety, mechanism, and therapeutic indication information.

---

Approved Routes and Forms

Корвитол is officially approved for oral administration via tablets/capsules (immediate-release Metoprolol Tartrate or extended-release Metoprolol Succinate) and intravenous (IV) injection (Tartrate), typically reserved for initial management in acute settings.

Administration Type	Formulation Example
Oral	Tablet (Immediate- or Extended-Release)
Intravenous	Injection (For acute care)

---

Dosing and Schedule Principles

Titration is mandatory for initiating therapy. For most conditions (Hypertension, Angina), dosage is adjusted at weekly or longer intervals. For Chronic Heart Failure, the dose is generally doubled every two weeks from a low starting dose, up to a target of 200 mg once daily. Dosing for hypertension can range from an initial 100 mg per day up to a maintenance of 450 mg (Tartrate) or 400 mg (Succinate ER) per day.

---

Key Administration Conditions

• Consistency with Meals: Oral doses must be taken with a meal or immediately following a meal to enhance and stabilize absorption. Consistency in relation to food is required.
• Extended-Release Integrity: Extended-release tablets must not be crushed or chewed to preserve the sustained-release mechanism. The capsule contents may be sprinkled on soft food (e.g., applesauce) and swallowed immediately.
• Discontinuation: Treatment must not be stopped abruptly. The dosage should be reduced gradually over a period of 1 to 2 weeks, as abrupt cessation is linked to procedural risks.

Recent Clinical Evidence

Clinical Trial Data

Research explored the profile of this molecule, a selective beta1-adrenergic receptor antagonist (beta-blocker, Metoprolol), in conditions such as hypertension, chronic stable angina, and post-myocardial infarction. Studies involved controlled trials across Phase I, II, and III stages.

• One large-scale study on patients following myocardial infarction documented a reduction in mortality and re-infarction rates over time in the treatment group.
• Studies investigating chronic stable angina reported measures related to exercise tolerance and the frequency of anginal episodes.
• Research on patients with heart failure (reduced ejection fraction) demonstrated that the administration of this class of beta-blockers was associated with lower rates of hospitalization.
• Study documentation included details on participant drug administration and dosing protocols.

Adjunctive Therapy and Comparative Data

Comparative trials have been conducted to evaluate this molecule against other beta-blockers in specific populations, such as heart failure.

• One major European trial compared this drug (Metoprolol) against a non-selective beta-blocker (Carvedilol) in patients with chronic heart failure. This study was noted to require further investigation in some areas, but reported differences in all-cause mortality between the two agents.
• Ongoing research continues to investigate the comparative effectiveness of different beta-blockers in various patient groups, including those with implanted cardioverter defibrillators (ICDs).

Safety Profile Summary

Safety studies investigated the effects across various subgroups. Adverse events documented across trials included temporary blurred vision, dizziness, fatigue, and mild headache in a small percentage of participants. Research examined the effects in individuals with conditions such as severe liver disease, as well as the impact on blood sugar levels.

Common questions about Корвитол (FAQ)

---

Q: What should I do if I am taking an ACE-inhibitor (e.g., lisinopril) and am prescribed this medication?

Official medication information notes a need for caution when using this drug alongside other medications associated with a condition called angioedema. Angioedema is a type of swelling beneath the skin, often affecting the face, lips, or throat. Since angiotensin-converting enzyme (ACE) inhibitors, such as lisinopril, are linked to angioedema, the product label indicates that taking them with this medication may increase the risk of this particular event.

---

Q: Can I take this medicine if I have a known allergy to other seizure or pain medicines?

Regulatory documents state that this medication is contraindicated, meaning it should not be used, if a person has a known hypersensitivity (allergy) specifically to the active substance, pregabalin, or to any of the inactive ingredients it contains. The presence of an allergy to other types of seizure or pain medicines does not automatically make this drug unsafe, but it is important to discuss specific allergies with a healthcare professional.

---

Q: Is it safe to drink alcohol while taking this medicine?

Official product information notes that using this medication with alcohol can increase central nervous system side effects. These effects may include feeling sleepy, dizzy, or experiencing impairment in thinking and judgment. Official guidance usually suggests avoiding or limiting the consumption of alcohol while this medication is being taken.

---

Q: Is this medicine safe for long-term use?

Official safety information notes reports of adverse events, such as angioedema, occurring during both the initial period and chronic (long-term) treatment. If the medication is stopped, the regulatory guidance states that the dose should be gradually reduced or 'tapered' over a minimum of one week. This process is intended to minimize the potential for withdrawal reactions.

---

Q: Can children 2 years old use this medicine for seizures?

According to the official product label, this medication is indicated for use as an add-on therapy for partial-onset seizures in children. It can be used in pediatric patients as young as 1 month of age and older. Dosing for young patients, as described in the official label, is calculated based on body weight.

How to Store and Dispose of Корвитол?

The storage and disposal of Корвитол (Metoprolol tablets) must follow specific regulatory guidelines to ensure product stability and safety.

Official Storage Conditions

Constraint	Requirement
Temperature	Store at room temperature (typically below 25 C).
Environment	Keep away from excess heat and moisture; do not store in the bathroom.
Packaging	Keep the medicine in its tightly closed original container.

Child Safety and Handling

This medication must be kept out of the sight and reach of children; safety caps should always be locked. If tablets are crushed, avoid breathing the dust and avoid contact with the skin.

Mandatory Disposal Protocol

Do not flush unused or expired tablets down the toilet or pour them into a drain. The preferred method for disposal is using a drug take-back program. If this is unavailable, mix the tablets with an undesirable substance (such as dirt or coffee grounds) and place the mixture in a sealed container before throwing it into the household trash.